Groundbreaking T-Cell therapy trial offers hope for kids with tough leukemia
NCT ID NCT05105152
Summary
This early-phase study is testing a new, genetically modified T-cell therapy called SC-DARIC33 in children and young adults (up to age 30) whose acute myeloid leukemia has returned or not responded to standard treatments. The main goals are to see if the therapy is safe to make and give, and to check for any early signs that it might help fight the cancer. Doctors will collect the patient's own T-cells, modify them in a lab to better target the leukemia, and then infuse them back into the patient.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA REFRACTORY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Seattle Children's Hospital
RECRUITINGSeattle, Washington, 98105, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.